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Synergy between RA and TLR3 promotes type I IFN-
dependent apoptosis through upregulation of TRAIL
pathway in breast cancer cells
AR Bernardo1, JM Cosgaya1, A Aranda1 and AM Jime´nez-Lara*1
Due to its ability to regulate the growth, differentiation and apoptosis of cancer cells, retinoic acid (RA) is considered a signaling
molecule with promising therapeutic potential in oncology. In this study, we show that RA is able to induce the intrinsic ability of
breast cancer cells to recognize double-stranded RNA (dsRNA) through the upregulation of Toll-like receptor 3 (TLR3)
expression. RA, co-administered with the dsRNA mimicker polyinosinic–polycytidylic acid (poly(I:C)), synergizes to mount a
specific response program able to sense dsRNA through the concurrent upregulation of TLR3, the dsRNA helicases melanoma
differentiation-associated antigen-5 (MDA-5) and RA-inducible gene-1 (RIG-1), and the dsRNA-activated protein kinase (PKR)
expression, leading breast cancer cells to specifically express downstream transcriptional targets of dsRNA sensors, such as
interferon-b (IFNb), interleukin-8 (IL-8), chemokine (C-C motif) ligand 5 (CCL5), and C-X-C motif Chemokine 10 (CXCL10). A TLR3-
dependent apoptotic program is also induced by RA and poly(I:C) co-treatment that correlates with the induction of the tumor
necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and contributes to block breast cancer cell proliferation. The
mechanisms of apoptosis induced by RA/poly(I:C) in breast cancer cells involve type I IFN autocrine signaling, caspase-8 and
caspase-3 activation, as well as TRAIL signaling. Our results reveal important links among RA, TLR3 and TRAIL and highlight the
combined use of RA and poly(I:C) as a potential effective tumor therapy by improving the apoptotic response of cancer cells with
low sensitivity to the action of synthetic dsRNA.
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Differentiation therapy by retinoic acid (RA) remains an
important cancer treatment modality for the management of
some types of cancer (e.g., acute promyelocytic leukemia
(APL)). RA, the active form of vitamin A, signals through three
RA receptors (RARa, -b, and -g) and three retinoid-X-
receptors (RXRa, -b, and -g), which form RXR/RAR hetero-
dimers. These receptors are the in vivo mediators of the
RA-induced signaling and control a plethora of gene
regulatory programs acting as ligand-dependent transcription
factors.1 RA regulates cell growth, differentiation and death,
and thus plays major roles in embryonic development and
tissue remodeling.2 RA has been also shown to inhibit breast
cancer cell growth and prevent mammary carcinogenesis in
animal models, a process that generally involves the induction
of apoptosis and cell-cycle arrest.3 Despite the remarkable
efficacy of all-trans RA in APL,4 it has shown limited success
in clinical trials of breast cancer.5,6 Research focused on the
actions of the RARs, on the regulation of their expression, and
on the identification of their target genes is key to improve RA
efficacy and to develop new therapies for cancer disease.
For the past 25 years, a special attention has been given to
adjuvants or enhancers of immunity for cancer therapy.
The Toll-like receptor (TLR) family recognizes pathogen-
associated molecular patterns specific for microbial compo-
nents.7,8 Mainly expressed in innate immune cells, TLRs
recognize these motifs and trigger innate immune activation
and, subsequently, adaptive immunity. Several TLR agonists
are currently being tested as adjuvants for anticancer
vaccines and therapies.9 TLR3 acts as a critical sensor of
double-stranded RNA (dsRNA) and has been found in
endosomal compartments or at the cell surface of conven-
tional dendritic cells, as well as in a variety of epithelial cells.8
In a similar way to natural dsRNA from viral origin, the
synthetic dsRNA analog polyinosinic–polycytidylic acid
(poly(I:C)) binds TLR3 leading to the activation of the
transcription factors nuclear factor-kB (NF-kB) and interferon
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regulatory factor 3 (IRF3), and of kinases such as p38 and
c-Jun N-terminal kinase (JNK), promoting the synthesis of
proinflamatory cytokines, costimulatory molecules and type I
interferons (IFNs). In fact, poly(I:C) was found to be a strong
IFN inducer.10,11 Additional cytosolic dsRNA receptors—
RA-inducible gene-1 (RIG-1) and melanoma differentiation-
associated antigen-5 (MDA-5)—have recently been identi-
fied.12 Because poly(I:C) promotes the activation of the
innate immunity and thus of long-lasting T cells immunity,13
it is of great interest as a potential anti-cancer agent.14–17
Importantly, it has recently been reported that TLR3 agonists,
especially poly(I:C), can directly kill cancer cells through
induction of apoptosis.14 Thus, TLR3 activation may cause
tumors to regress by increasing apoptosis of cancer cells in a
cell-autonomous manner and by directly or indirectly recruit-
ing leukocytes, resulting in tumor lysis by natural killer and
cytotoxic T-cells.
In this study, we report that RA-induced growth inhibition is
accompanied by induction of TLR3 gene expression in breast
cancer cells. We found that treatment with RA and poly(I:C)
synergistically inhibited the growth and induced the apoptosis
of breast cancer cells, which is accompanied by the
concomitant upregulation of dsRNA receptor expression
TLR3, RIG-1, MDA-5 and the dsRNA-activated protein kinase
(PKR), and their downstream transcriptional target genes,
interleukin-8 (IL-8), chemokine (C-C motif) Ligand 5 (CCL5),
C-X-C motif Chemokine 10 (CXCL10) and IFNb. Our results
suggest that RA and poly(I:C) co-treatment induces cell death
in a TLR3-dependent manner, which involves type I IFN
autocrine signaling, caspase-8 and caspase-3 activation as
well as the expression and activity of the tumor necrosis factor
(TNF)-related apoptosis-inducing ligand (TRAIL).
Results
RA and poly(I:C) co-treatment inhibits breast cancer cell
growth. Data obtained in our laboratory indicated that
9-cis-retinoic-acid (9cRA) induce the upregulation of TLR3
in SK-BR-3 cells (AMJ-L, unpublished results). In order to
corroborate these data and to increase the relevance of the
results, we decided to broaden the study and analyzed TLR3
expression in a panel of six human breast cancer cell lines
after 9cRA treatment. 9cRA upgregulated TLR3 mRNA
expression in all tested cell lines (Figure 1a). Since it is well
recognized that RA and TLR3 agonists, on their own, can
exert anti-proliferative effects in certain breast cancer cells,
we decided to investigate the effect of a combined treatment
of both. For this purpose, we performed dose-response
experiments in several breast cancer cell lines treated with
9cRA in the presence or absence of poly(I:C). As expected,
treatment of SK-BR-3 cells with 9cRA at the pharmacological
concentration of 10 6M displayed a weak growth inhibitory
effects at 48 h, whereas no effects on cell proliferation could
be seen after addition of poly(I:C) alone at any concentration
used. Interestingly, 9cRA and 50 mg/ml poly(I:C) co-treatment
exerted profound anti-proliferative effects in these cells
(Figure 1b). At this concentration, 9cRA and poly(I:C) co-
treatment inhibited cell growth in a time-dependent manner in
SK-BR-3 cells, by about 60% and above 80% at 48 h and
72 h, respectively (Supplementary Figure S1). Similar results
were obtained for H3396, ZR-75-1, and T47D cells. However
in these cells, poly(I:C) alone was already able to inhibit
growth, while 9cRA increased the sensitivity of the cells to
the anti-proliferative action of poly(I:C). Taken together,
these results suggest that the two signaling pathways can
cooperate in the control of breast cancer cell proliferation.
RA and poly(I:C) co-treatment induces caspase-
dependent cell death. In order to find out whether cell
death contributes to the anti-proliferative effect induced by
9cRA and poly(I:C) co-treatment in SK-BR-3 cells, we
analyzed the sub-G1 cell-population as a measure of cell
death. As shown in Figure 2a, neither the treatment with
9cRA nor with poly(I:C) alone had any noticeable effect on
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Figure 1 Regulation of TLR3 expression by 9cRA in breast cancer cells: 9cRA
and poly(I:C) cooperate to inhibit the growth of breast cancer cells. (a) Quantitative
RT-PCRs were performed with primers for TLR3 and b-actin mRNA using total RNA
of different breast cancer cells treated with either vehicle (open bars) or 9cRA (black
bars) for 48 h. Data represent the mean±S.D. of three different experiments.
Asterisks denote statistically significant differences against the corresponding
untreated cells (**Po0.01; ***Po0.001). (b) SK-BR-3, ZR-75-1, H3396, and T47D
cells were treated with varying concentrations of poly(I:C) for 48 h in the presence or
absence of 9cRA (10 6 M). Viability was measured by crystal violet. The results are
shown as percentage of the values obtained in control conditions (cells grown in the
presence of vehicle). All values are shown as the mean±S.D. of three different
experiments
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SK-BR-3 cell viability. However, 9cRA and poly(I:C) co-
treatment dramatically induced cell death. Apoptosis induced
by 9cRA and poly(I:C) co-treatment was also found in ZR-75-
1 cells, although in these cells, poly(I:C) on its own clearly
increased the percentage of apoptotic cells. In the human
breast cancer cell lines Hs578T, H3396 and T47D, 9cRA
and/or poly(I:C) failed to induce apoptosis (data not shown).
However, the addition of cycloheximide (CHX) to the media
was sufficient to render Hs578T sensitive to the pro-
apoptogenic effects of 9cRA and poly(I:C) co-treatment,
suggesting that an unstable inhibitor of 9cRA/poly(I:C)-
induced apoptosis is expressed in this particular cell line
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Figure 2 Induction of apoptosis in breast cancer cells by 9cRA and poly(I:C) treatment. (a) Breast cancer cells were treated with 9cRA (10 6M), poly(I:C) (50 mg/ml in all
cell lines except for ZR-75-1 cells that were treated with 12.5mg/ml), or the combination of both for 48 h, and cell death was assayed by PI staining and FACS analysis. In the
case of Hs578T, H3396, and T47D cell lines, cells were pretreated with 9cRA for 24 h and cycloheximide (CHX) at a concentration of 2.5mg/ml was added 2.5 h prior to
stimulation with poly(I:C) or vehicle for other additional 24 h. Data represent the mean±S.D. of three different experiments. (b) SK-BR-3 cells were treated with vehicle (open
bars) or 50mg/ml of poly(I:C) (black bars) in the presence of increasing concentrations of 9cRA. Cell death was determined as in (a) after 48 h. Data represent the mean±S.D.
of three different experiments. (c) SK-BR-3 cells were treated with vehicle (open bars) or with 50 mg/ml of poly(I:C) (black bars) in the presence of agonists specific for RAR
(TTNPB), RXR (LG268) or both receptors (9cRA) for 48 h, followed by PI staining and FACS analysis. Data are shown as the mean±S.D. of three different experiments.
(d) SK-BR-3 cells were treated for 48 h with vehicle, 9cRA (10 6M), 50mg/ml of poly(I:C) or 100mg/ml of poly(A:U) as indicated. The percentage of cells positive for PI staining
was quantified as in (a). Data represent the mean±S.D. of three different experiments. (e) Immunoblot showing pro-caspase-8 cleavage and induction of active caspase-3
after treatment with 9cRA (10 6M), 50mg/ml of poly(I:C) or the combination of both. The cleavage products of pro-caspase-8 are indicated as p43/41 and p18. b-Actin was
used as loading control. The immunoblots show representative results from three independent experiments
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that has to be degraded in order to allow apoptosis induction.
In contrast, no effect of CHX could be detected in the other
two cell lines (H3396 and T47D), suggesting that other
mechanisms could also account for apoptosis resistance to
9cRA/poly(I:C).
Next, we decided to analyze more thoroughly the apoptotic
pathway(s) activated in SK-BR-3 and ZR-75-1 cells conse-
quently to 9cRA/poly(I:C) co-treatment. Our results show that
9cRA cooperates with poly(I:C) to induce apoptosis in a dose-
dependent manner in SK-BR-3 cells (Figure 2b). Since 9cRA
is a pan-RAR and -RXR agonist, we used specific agonists to
test the contribution of each of these receptors to the cell
death induction promoted by 9cRA and poly(I:C) co-treat-
ment. As shown in Figure 2c, while TTNPB, an RAR-agonist,
clearly cooperates with poly(I:C) to induce the apoptosis of
SK-BR-3 cells, the specific RXR-agonist LG-100268 does not
affect the viability of these cells, showing that RARs are the
receptors involved. Cooperation between 9cRA and poly(I:C)
to induce apoptosis seems specific for poly(I:C) since another
dsRNA, polyadenylic–polyuridylic acid (poly(A:U)), does not
synergize with 9cRA to induce apoptosis in SK-BR-3 cells
(Figure 2d). Moreover, 9cRA and poly(I:C) co-treatment
activates caspase-8 and caspase-3 as assessed by western
blot in SK-BR-3 cells (Figure 2e). Taken together, these
results suggest that an RAR-mediated caspase-dependent
cell death mechanism contributes to the 9cRA/poly(I:C)-
driven anti-proliferative effects in breast cancer cells.
RA and poly(I:C) co-treatment enhances the expression
and signaling of dsRNA sensors. Since our observations
show that TLR3 mRNA is upregulated by 9cRA in breast
cancer cell lines, we next sought to investigate whether 9cRA
and/or poly(I:C) regulate the expression of other dsRNA
sensors in SK-BR-3 and ZR-75-1 cells that could act as
potential mediators of 9cRA/poly(I:C)-driven apoptosis. As
shown in Figure 3a, TLR3 mRNA was upregulated by 9cRA
but not by poly(I:C) in SK-BR-3 cells. Importantly, 9cRA/
poly(I:C) co-treatment synergistically induces the expression
of TLR3 (Figure 3a). Similar results were seen at the protein
level (Figure 3c). RIG-1 mRNA was also strongly upregulated
by 9cRA alone, while no significant induction of MDA-5 and
PKR expression by 9cRA was seen in SK-BR-3 cells. Note
that, on its own, poly(I:C) did not induce the expression of
these genes in this cell line. Interestingly, the combination
of both 9cRA and poly(I:C) resulted in a synergistic induction
of RIG-1, MDA-5 and PKR above the levels seen with either
compound alone (Figure 3e). Similar results were obtained
with ZR-75-1 cells albeit induction of these genes by 9cRA was
lower than in SK-BR-3 cells, and poly(I:C) alone notably
regulated the expression of all these genes. As it was observed
for SK-BR-3 cells, 9cRA/poly(I:C) co-treatment synergistically
induced the expression of these genes in ZR-75-1 cells
(Figure 3b, d, and f). These data suggest that 9cRA and
poly(I:C) crosstalk to amplify an innate immune signaling
pathway that drives breast cancer cells to apoptosis.
Next, we decided to investigate whether 9cRA and poly(I:C)
crosstalk produces an amplification of dsRNA receptor
signaling by analyzing the expression of several downstream
transcriptional targets in breast cancer cells such as IFNb, and
some interleukins and chemokines involved in the activation
and chemoattraction of immune cells. As shown in Figure 4,
the expression of IFNb, IL-8, CCL5, and CXCL10 were
synergistically induced after 9cRA/poly(I:C) co-treatment, but
not with either treatment alone.
Type I IFN signaling is involved in RA/poly(I:C)-induced
apoptosis. As IFNb has been described as a potent
apoptotic inducer in several cell models, we sought
to investigate whether that could be also the case for
SK-BR-3 cells. Despite the dramatic induction of IFNb by
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Figure 3 9cRA and poly(I:C) cooperate to induce the expression of the dsRNA sensors TLR3, RIG-1, MDA-5, and PKR in SK-BR-3 and ZR-75-1 breast cancer cells. (a, b)
Quantitative RT-PCR was performed with primers for TLR3 and b-actin mRNA using total RNA from SK-BR-3 (a) or ZR-75-1 (b) cells treated with vehicle or with poly(I:C) in
the absence (open bars) or presence of 9cRA (black bars) for 24 h. Data represent the mean±S.D. of three different experiments. (c, d) TLR3 protein level was determined in
SK-BR3 (c) or ZR-75-1 (d) cells after treatment with 9cRA, poly(I:C) or the combination of both for 48 h using b-actin as a loading control. The immunoblots show
representative results from three independent experiments. (e, f) Quantitative RT-PCR was performed with primers for RIG-1, MDA-5, PKR, and b-actin mRNA using total
RNA from SK-BR-3 (e) or ZR-75-1 (f) cells treated as described in (a). All values are shown as the mean±S.D. of three different experiments
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9cRA/poly(I:C), recombinant IFNb alone or in combination
with 9cRA was a poor inducer of cell death in SK-BR-3 even
at high doses. By contrast, recombinant IFNb cooperated with
poly(I:C) to elicit a dramatic induction of cell death in these
cells (Figure 5a). To determine the role of type I IFNs in 9cRA/
poly(I:C)-induced apoptosis, we assessed the neutralization
of type I IFN receptor (IFNR) with specific monoclonal
antibodies in 9cRA/poly(I:C)-treated cells. As shown in
Figure 5b, the neutralization of type I IFNR significantly
reduced 9cRA/poly(I:C)-induced apoptosis of SK-BR-3 cells,
demonstrating that type I IFN signaling is involved in 9cRA/
poly(I:C)-driven cell death. These results establish that type I
IFN signaling is at least partially required for 9cRA/poly(I:C)-
triggered citotoxicity.
TRAIL expression is induced by RA/poly(I:C)
co-treatment in breast cancer cells. The activation of
caspase-8 implies the potential involvement of the apoptotic
extrinsic pathway triggered by 9cRA/poly(I:C) co-treatment.
TRAIL, an IFN target gene, is a death ligand that triggers cell
death via the extrinsic pathway.18 Since RA induces
apoptosis of cancer cells by inducing TRAIL expression19,20
and TRAIL is involved in poly(I:C)-driven apoptosis in
endothelial cells,21 we reasoned that TRAIL could be a
mediator of 9cRA/poly(I:C) pro-apoptotic signaling in breast
cancer cells. As expected, 9cRA induced TRAIL mRNA level
(E10-fold) in SK-BR-3 cells, and a similar induction was
observed with poly(I:C) alone. Importantly, 9cRA/poly(I:C)
co-treatment led to a synergistic upregulation of TRAIL
mRNA (41500-fold), as shown in Figure 6a. Protein
immunoblotting revealed that synergistic upregulation of
TRAIL by 9cRA/poly(I:C) co-treatment occurs in a time-
dependent manner and correlates with caspase-3 and
caspase-8 activation (Figure 6b). Similar results were
obtained in ZR-75-1 cells with the only difference that
poly(I:C), on its own, strongly induced both TRAIL mRNA
and protein levels in these cells (Figure 6c and d). Therefore,
these results indicate that 9cRA and poly(I:C) signaling can
cooperate to synergistically induce TRAIL and its expression
correlates with the activation of different apoptotic markers.
TLR3 is required for RA/poly(I:C)-induced TRAIL
upregulation and breast cancer cell apoptosis. In order
to determine the involvement of TLR3 in 9cRA/poly(I:C)-
driven cell death, TLR3 expression was suppressed through
transfection of small interfering RNAs (siRNAs) (Figure 7b).
Depletion of TLR3 protein levels virtually abrogated
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9cRA/poly(I:C)-induced apoptosis, whereas transfection with
scrambled-siRNAs had no effect (Figure 7a). To further
confirm the above results, we compared the level of
activation of caspase-8 and -3 by protein immunoblotting in
the presence or absence of TLR3 siRNAs. While the levels of
cleaved caspase-8 and -3 were induced by 9cRA/poly(I:C) in
control cells, TLR3 depletion abolished caspase activation by
9cRA/poly(I:C) (Figure 7b). Moreover, 9cRA/poly(I:C)-driven
TRAIL induction was completely abrogated by TLR3 siRNAs
(Figure 7b). These results reveal that: (i) TLR3 is critically
involved in 9cRA/poly(I:C)-driven apoptosis and (ii) TLR3
mediates the induction of the death ligand TRAIL by 9cRA/
poly(I:C) in SK-BR-3 cells, reinforcing our hypothesis that
TRAIL mediates 9cRA/poly(I:C)-driven apoptosis.
TRAIL induction is critically involved in RA/poly(I:C)-
induced apoptosis. To confirm that TRAIL induction is
responsible for 9cRA/poly(I:C)-induced apoptosis, TRAIL
protein was downregulated through transfection of siRNAs
(Figure 8b). Interestingly, our results show that 9cRA/
poly(I:C)-induced apoptosis was highly reduced when TRAIL
levels were downregulated using siRNAs (Figure 8a). To
further validate this, the levels of caspase-8 and -3 activation
were compared in SK-BR-3 cells transfected with siRNAs
against TRAIL versus scrambled siRNAs. While caspase-8
and -3 cleavage was induced by 9cRA/poly(I:C) in scrambled
siRNA-transfected cells, downregulation of TRAIL significantly
abolished caspase-8 and -3 activation by 9cRA/poly(I:C)
(Figure 8b). These results suggest that TRAIL plays a main
role in 9cRA/poly(I:C)-driven apoptosis in SK-BR-3 cells.
Discussion
In the present study, we provide evidence that RA is able to
induce the expression of TLR3, allowing breast cancer cells to
sense and respond to the synthetic dsRNA poly(I:C), and
driving breast cancer cells to apoptosis. Apoptosis induced by
this combination treatment is a caspase-, TLR3-, type I
IFN- and TRAIL-signaling-dependent process. Our findings
suggest that combined treatments with RA may improve the
apoptotic cellular response in those cancer cells insensitive or
with low sensitivity to the anti-tumor action of synthetic
dsRNA.
The anti-tumor activity of poly(I:C) is well known since
decades. Recent data have shown that poly(I:C) binding to
TLR3 triggers apoptosis of human cancer cells.14,22 In
addition, poly(I:C) has indirect anti-tumor activities since it is
a potent inducer of type I IFNs,23 which are known to exert
anti-tumor actions on a variety of tumor cells. It has
been shown that IFNs have anti-proliferative and pro-
apoptotic effects in an extensive panel of malignant cells.24
Since the late 1960s, numerous studies have been performed
using synthetic dsRNA to inhibit tumors in experimental
animal models as well as in clinical trials. The anti-tumor
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activity of poly(I:C) is mainly due to its ability to induce IFNs,
which either kill directly tumor cells or enhance the host
immune response.
On the other hand, RA, due to its strong anti-proliferative
and differentiative potential, has been widely used in both
cancer therapy and cancer prevention.25 RA derivatives are
currently used in the treatment of APL and cutaneous
T-cell lymphomas, but they are also effective on B-cell
malignancies.3 In addition to the induction of differentiation,
RA is able to initiate several other biological programs that
may contribute to its therapeutic potential. Indeed, it has been
shown that RA induces apoptosis of APL cells andAPL patient
blasts through selective paracrine action of TRAIL.19 In breast
cancer cells, previous data have shown that RA inhibits the
proliferation of a large number of cell lines and xenograft
models by modulating the expression of several genetic
programs. In addition to directly target neoplastic cells,
accumulated evidence indicate that RA may also exerts
immunomodulatory effects. To a certain extent, the efficacy of
RA in cancer treatment may reside in its ability to also
modulate the function of immune effectors.26
Our findings show that RA induces TLR3 expression in
several breast cancer cell lines, suggesting that TLR3
activation may play an important role in RA action in breast
cancer cells. Importantly, RA regulation of TLR3 expression
may be indirect or depend on intermediary short-lived
protein(s), since incubation with CHX abrogates induction of
TLR3 mRNA by RA (data not shown). It has been previously
shown that the TLR3 promoter contains an ISRE/IRF-E and a
STAT-binding site.27 These consensus sites might regulate
the response of TLR3 to RA since it has been shown that RA
can control the expression and activity of transcription factors
such as IRF1 and STAT1 in cancer cells.20,28–31 Further
studies will be required to know the molecular mechanism
underlying the regulation of TRL3 expression by RA. Based
on our finding that TLR3 expression is enhanced by RA, we
hypothesized that RA could cooperate with TLR3 agonists to
enhance their anti-cancer action. In our study, we found that (i)
RA is able to sensitize breast cancer cells to the anti-
proliferative effects of poly(I:C) and (ii) RA does not induce a
noticeable cell death in breast cancer cells by itself but it
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synergizes with poly(I:C) to increase cell death. This synergy
is specific for poly(I:C) since another TLR3 ligand such as
poly(A:U) failed to cooperate with RA, even at the relative
high concentration used in our study. Our results suggest
that the increased levels of TLR3 obtained following treatment
with RA are sufficient to allow signaling by poly(I:C) but
not by poly(A:U). In this regard, previous reports have
shown a similar activity for both TLR3 ligands but with a
significant lower potency for poly(A:U) compared with
poly(I:C).32,33 Probably, differences in potency might be
proportional to the ability of these ligands to mediate
TLR3 multimerization and subsequent signaling. Alterna-
tively, a different affinity of TLR3 for poly(I:C) and poly(A:U)
could also account for the differences found between these
two TLR3 ligands.
Notably, our results also show that RA and poly(I:C)
synergistically induce the expression of TLR3, MDA-5,
RIG-1, and PKR, thus amplifying the cellular response to
poly(I:C). Increased expression of these dsRNA sensors
could enhance the susceptibility of breast cancer cells to
poly(I:C)-induced apoptosis as it occurs in other cell systems
where ectopic overexpression of TLR3 increases the sensi-
tivity of low TLR3-expressing neuroblastoma cells to
poly(I:C).34 Thus, our results show that RA is able to modulate
the expression of key innate immune players allowing breast
cancer cells to sense and respond tomimickers of viral dsRNA
such as poly(I:C). Given that knockdown of TLR3 completely
abolished RA/poly(IC) induced apoptosis in SK-BR-3 cells, it
is unlikely that RIG-1 or other dsRNA sensors play an
important role in RA/poly(I:C)-induced apoptosis although
we cannot discard that these cytoplasmic dsRNA receptors
could be involved in other aspects of RA/poly(I:C) crosstalk.
In response to RA/poly(I:C) treatment, SK-BR-3 cells
produce high amounts of IFNb and TRAIL as well as the
activation of caspase-3 and caspase-8. It has been shown
that type I IFNs can directly contribute to tumor cell death in a
caspase-dependent manner,35 or indirectly contribute to the
upregulation of cytotoxic molecules such as TRAIL.36,37
Molecular events involved in cell death induced by RA/
poly(I:C) co-treatment include type I IFNR signaling that
seems to be required but not sufficient for apoptosis, since
recombinant IFNb, per se, or in combination with RA does not
recapitulate the proapoptogenic activity of RA/poly(I:C) in
breast cancer cells. However, recombinant IFNb and poly(I:C)
co-treatment is able to induce apoptosis in breast cancer cells
as it has been shown for other cell types. Thus, our findings
suggest that, besides of type I IFN signaling, additional signals
coming from poly(I:C) are required to induce a fully apoptotic
program. It is likely that IFNb contributes to TRAIL induction
by RA/poly(I:C) in breast cancer cells, as it occurs in other
cellular systems but that additional signals, apart from IFNb,
are required to sense and transduce TRAIL death signaling.
Considering the contribution of type I IFNs in apoptosis
induced by RA/poly(I:C), it is tempting to speculate that
differences in the ability to produce and/or to respond to type I
IFNs consequently to RA/poly(I:C) co-treatment could explain
the observed variability in RA/poly(I:C)-induced cell death in
different cellular contexts. On the other hand, it has been
shown that RA can synergize with IFNs to induce several
biological responses. In that sense, RA directly induces the
expression of two transcription factors, STAT1 and IRF1, that
play central roles in the IFN signal transduction path-
ways.20,28,29,38–41 In addition, it has been proposed that RA
may indirectly activate IRF1 expression by a mechanism
involving NF-kB.42 RA also enhances IFNb-induced expres-
sion and phosphorylation of STAT1 in human leukemia cells43
explaining the RA/IFN synergy found in these cells. Therefore,
it is possible that RA could be able to enhance poly(I:C)
signaling in breast cancer cells by boosting type I IFN
signaling.
Our findings also show that the activation of caspases
and induction of TRAIL expression by RA/poly(I:C) require
the engagement of TLR3, as depletion of TLR3 abrogates
caspase-8 and caspase-3 activation as well as TRAIL
induction. TRAIL selectively induces apoptosis of transformed
and virally infected cells. Several studies have suggested
that TRAIL may have a role as a tumor suppressor since
TRAIL induces apoptosis selectively in cancer cells, while
normal cells are largely insensitive to its apoptotic activity.44
Furthermore, TRAIL signaling pathway is critically involved in
the immune surveillance against primary and metastatic
tumors through natural killer cells.45 We have previously
reported that TRAIL expression is remarkably enhanced in
breast cancer cells after RA treatment.20 Our experiments
are in agreement with our previous findings, and also show
that RA can synergistically cooperate with poly(I:C) to
induce TRAIL. Thus, in our study TRAIL has emerged as a
likely candidate to mediate the apoptotic effect of RA/poly(I:C)
combination in breast cancer cells. Notably, our results show
that depletion of TRAIL abrogates apoptosis induced by RA/
poly(I:C), showing that TRAIL is a main player in RA/poly(I:C)-
induced apoptosis. Based on our results, we propose that RA/
poly(I:C) treatment induces breast cancer cell apoptosis via
TLR3-dependentmechanisms. RA/poly(I:C) stimulation leads
to upregulation of IFNb in breast cancer cells, which in turn
may act in an autocrine manner to induce the expression of
TRAIL, which is ultimately responsible for cell death induction
by RA/poly(I:C) in breast cancer cells. Additionally, as
poly(I:C) exerts direct cytostatic/cytotoxic effects against a
wide spectrum of tumor cells, we would expect that any
poly(I:C)-responsive tumor cell line that keeps an intact RA
signaling axis and retains the ability to produce and respond to
type I IFNs could be able to mount a synergistic anti-tumor
response to a combination of RA and poly(I:C).
Materials and Methods
Cell lines and reagents. Hs578T, H3396, T47D, ZR-75-1, and BT-474 cells
were cultured in RPMI (Life Technologies, Carlsbad, CA, USA) or Dulbecco’s
modified media (Sigma, St Louis, MO, USA), in the case of SK-BR-3 cells,
containing red phenol with 10% (v/v) fetal calf serum (Life Technologies) and 2 mM
glutamine (Life Technologies). For the T47D cell line, medium was supplemented
with 0.6mg/ml insulin (Sigma). All cells were incubated under standard culture
conditions (37 1C, 5% CO2).
9-cis-RA (Sigma), the RAR-specific synthetic retinoid TTNPB (Sigma) and the
RXR-specific rexinoid LG-100268 (Ligand Pharmaceuticals Inc., La Jolla, CA, USA)
were dissolved in ethanol and used at 1 10 6 M unless otherwise indicated.
Poly(I:C), high molecular weight, from Invivogen (San Diego, CA, USA), was
dissolved in water and used at a concentration of 50mg/ml, with the exception of ZR-
75-1 cells where 12.5mg/ml were used. Poly(A:U) (Invivogen) was dissolved in
water and used at 100mg/ml. Type I IFNR-blocking mAb was purchased from PBL
Interferon Source. Recombinant IFNb and CHX were obtained from Sigma.
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Proliferation assays. Cells were fixed in 1% of glutaraldehyde for 10 min,
washed with PBS 1 , and stained with 0.1% (w/v) crystal violet staining solution
for 30 min. After extensively rising with deionized water, the cells were air-dried,
the dye was taken out in 10% (v/v) acetic acid and the optical density was
measured at 590 nm.
Measurement of cell death. Sub-G1 cell-population was quantified by
single staining (propidium iodide, PI), according to standard procedures. Briefly,
the cells were trypsinized and 2.5 105 cells were washed with PBS 1 ,
incubated overnight at 4 1C in a hypotonic buffer containing PI (0.1% (v/v) Triton
X-100, 0.1% (w/v) sodium citrate and 50 mg/ml PI), and analyzed by flow
cytometry (FACSCalibur, Becton Dickinson, Heidelberg, Germany).
Western blotting. Caspase-3, -8 (Cell Signaling, Danvers, MA, USA),
b-actin-HRP (Sigma), TLR3 and TRAIL (R&D Systems, Minneapolis, MN, USA)
antibodies were used to probe blots of extracts prepared using Triton Lysis buffer
(10 mM Tris pH 7.4, 137 mM NaCl, 2 mM EDTA, 1% (v/v) Triton X-100, 25 mM
b-glycerophosphate, 1 mM sodium orthovanadate, 2 mM sodium pyrophosphate,
10% glycerol, 1 mM PMSF, and protease inhibitors cocktail). Immune complexes
were detected by chemiluminescence (GE Healthcare Biosciences, Pittsburgh,
PA, USA).
Gene knockdown by siRNA. SK-BR-3 breast cancer cells were seeded
24 h prior to transfection with 100 nM ON-TARGETplus SMARTpool (Dharmacon,
Thermo, Lafayette, CO, USA) for scrambled, TLR3 and TRAIL siRNAs using
DharmaFECT-2 as transfection reagent following the manufacturer’s instructions.
After 16 h, siRNA–lipid complexes were removed and cells were allowed to
recover for 72 h in complete medium before ligand treatment.
RNA extraction and quantification by RT-qPCR. Total RNA was
isolated using Tri-Reagent (Sigma), as described by the manufacturer, and 1 mg of
RNA was used in a reverse transcription reaction using iScript cDNA synthesis kit
from Bio-Rad (Berkeley, CA, USA). Quantitative PCR was performed using the FS
Universal SYBR Green Master Mix (Roche, Basel, Switzerland) on a Stratagene
Mx3005P real-time PCR thermal cycler. Relative changes in mRNA levels of
genes were assessed using the 2(DDCT) method and normalized to the
housekeeping gene b-actin. The primers used are indicated in Supplementary
Table 1.
Statistical analysis. Results are expressed as mean±S.D. Statistical
significance was assessed by two-tailed unpaired Student’s t-test using the
Microsoft Excel software (version 11.5.4) (Redmond, WA, USA). Differences were
considered significant when Po0.05. Statistical significance was expressed by
asterisks (*Po 0.05; **Po0.01; ***Po0.001).
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